A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901

Riichiroh Maruyama, Noriyuki Ebi, Junji Kishimoto, Masato Kato, Tokujiro Yano, Yoshinori Nagamatsu, Shuichi Tsukamoto, Shinji Akamine, Sho Saeki, Yukito Ichinose

Research output: Contribution to journalArticle

9 Citations (Scopus)


Background: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. Methods: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. Results: The completion rate of eight cycles was 70.8 % [95 % confidence interval (CI) 52.7-89.0 %]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 % (95 % CI 30.0-70.0 %). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 %. Conclusions: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalInternational Journal of Clinical Oncology
Issue number1
Publication statusPublished - Feb 1 2014


All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this